The Anticancer Drugs
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 2945
Special Issue Editors
Interests: anticancer therapy; personalized oncology; new drug development; microbiome; immunotherapy; cancer microenvironment; cancer cells culture; cancer stem cells
Special Issues, Collections and Topics in MDPI journals
Interests: molecular markers of the effectiveness of oncological treatment; epigenetic factors affecting clinical decisions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a serious problem that presents a huge threat to human health. During the last few years, there has been continued progress in anticancer drug development.
New agents ranging from small molecules to engineered antibodies and immune modulators have been approved for cancer treatment. Targeting drugs specifically to cancer cells can minimize the toxic effects on normal, healthy cells.
This Special Issue on “The Anticancer Drugs” aims to be an open forum where researchers may share their experiences and findings in this promising field. It is focused on the comprehensive and critical examination of current and emerging research on the design and development of advanced anticancer and their application to experimental and clinical therapeutics.
Contributions to this issue, in the form of both original research and review articles, may cover all aspects of new discovery and development of new therapeutic agents for cancer, using the newest techniques of biotechnology, pharmacology, and genetic engineering.
Prof. Dr. Anna Bajek
Prof. Dr. Krzysztof Roszkowski
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer therapy
- drug development
- personalized cancer treatment
- nanotechnology
- drug resistance in cancer
- drug design
- resistance
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
